Abstract 9P
Background
Tissue-resident memory (TRM) T cells have emerged as key players in cancer immunosurveillance, and their presence has been linked to a favorable clinical outcome in solid cancer patients. Liver metastases exhibit a highly immunosuppressive tumor microenvironment, however, the role and clinical impact of TRM cells infiltration in colorectal cancer remains elusive.
Methods
An exhaustive profiling was conducted on tumor-infiltrating lymphocytes isolated from 27 patients’ colorectal cancer (CRC) liver metastases. Cytokine production was evaluated in in vitro-activated TRM and non-TRM cells. 3D spheroid models were also used to study CXCR6+/- TRM cells cytotoxicity. Prognostic value of TRM cells was assessed. Single-cell RNAseq data were analyzed to investigate the transcriptomic profile of TRM cells subsets.
Results
Our analyses showed that only infiltration with CD103+CD69+ TRM cells was predictive of recurrence-free survival (RFS). However, CXCR6 expression on this TRM subset helped to stratify this population’s prognostic impact and was associated with shorter RFS. CXCR6 expression was inversely correlated to PD-1, HLA-DR, and CD39 expression, three well-validated biomarkers of tumor-reactive T cells. Strikingly, the expression of PD-1 in this TRM population was associated with improved patients’ prognosis. Interestingly, both in vitro and single-cell RNAseq data analyses revealed that CXCR6-PD1+ TRM cells showed significantly lower levels of TIM3 and LAG3 expression compared to CXCR6+PD1- that could be explained by a non-terminal exhausted state. Although both TRM populations presented high production levels of IFNg, GZMB, and IL-2; CXCR6-PD1+ TRM cells produced higher levels of TNFa. We next assessed TCF1 and TOX expression. Interestingly, CXCR6+PD1- TRM cells were more TCF1-TOX+, contrarily to CXCR6-PD1+ TRM cells that were more stem-like ‘TCF1-TOX+’. Finally, CXCR6-PD1+ TRM cells showed a significant increase in Ki67 expression.
Conclusions
We identified a novel population of TRM cells CXCR6-PD1+ that exhibit a ‘stem-like’ phenotype with higher proliferation capacity and are associated with improved prognosis in metastatic CRC patients.
Legal entity responsible for the study
UMR RIGHT 1098.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract